The content of this page is intended for healthcare professionals only.

Are you a professional?

Why should I choose LoFric?

LoFric® catheters have been on the market for more than 30 years. They are the most well-documented and tested catheters available. In fact, LoFric is the only hydrophilic catheter that can prove it reduces the risk of long-term complications.

Clean intermittent catheterisation is a painless therapy. The unique coating of LoFric catheters makes them as slippery on insertion as withdrawal. It is called Urotonic™ Surface Technology. This therapy and the social acceptance is nowadays very high.

In most ways, the therapy with LoFric catheters improves the quality of life and with its ease of use it is a safe product to rely on.

Over the years, we have also innovated new catheters that are more discreet and even easier to use to make life simpler for users.

Today we have a wide range of products - longer and shorter catheters with different packaging, functions and shapes. There's a LoFric catheter for everyone.

Behind LoFric, you will find a dedicated team who believe in what we do. We are well known by customers and healthcare professionals for our expertise and commitment to urological products, our services and support. We work for a world where urinary issues do not affect people´s potential to live a full and free life.

why should i choose lofric list of statistics full width statistics

LoFric reduces the risk of both pain and damage...

LoFric catheters are coated with our unique Urotonic™ Surface Technology, which means that LoFric’s surface has the same properties as your urethra – the salt concentration is the same as in urine. This ensures that the catheter remains smooth, comfortable and safe, both during insertion and withdrawal.

...and it is scientifically proven

LoFric are the only catheters proven in multiple studies to be safe for long-term use.

1. 7 years follow up of 30 LoFric patients. Waller et al. J Urol 1995;153:345-8 2. Survey in 288 long-term (10 years) LoFric users. Hakansson et al. Urol Nurs. 2015;35:239-47  3. Meta-analysis of 464 patients. Li et al. Arch Phys Med Rehabil. 2013;94:782-7